Abstract 11197: Comparison of Long-Term Survival According to the Presence of Metabolic Syndrome in Patients With Acute Myocardial Infarction After Successful Percutaneous Coronary Intervention With Drug-Eluting Stents
Introduction: Despite the significance of coronary reperfusion in AMI, the prognostic impact of MS has been investigated under inconsistent reperfusion therapy in AMI patients.
Hypothesis: We evaluate long-term survival according to the presence of metabolic syndrome (MS) in patients with acute myocardial infarction (AMI) undergoing successful percutaneous coronary intervention (PCI) with drug-eluting stents (DES).
Methods: Three-year clinical outcomes, including all-cause death and the composite of cardiac death or myocardial infarction, were evaluated according to MS status for 963 AMI patients treated with successful PCI with DES.
Results: This study included 494 subjects with MS (51%) and 469 subjects without MS (49%). The incidence of multivessel disease and the mean number of implanted stents were significantly higher in MS patients than in non-MS patients. The occurrence of all-cause death (5.9% vs. 6.4%, P=0.789) and the composite outcomes (5.1% vs. 6.2%, P=0.485) did not differ significantly between patients with and without MS. Cox regression models revealed that MS had no significant impact on all-cause death (hazard ratio [HR], 0.91; 95% confidence interval [CI], 0.55-1.52; P=0.726) or the composite outcomes (HR, 0.81; 95% CI, 0.48-1.39; P=0.448). Obesity was associated with a decreased risk of all-cause death and the composite outcomes among all MS components.
Conclusion: No difference was observed in long-term survival according to the presence of MS in AMI patients after successful PCI with DES. This suggests that reperfusion therapy using PCI with DES is equally beneficial in AMI patients with and without MS.
- © 2013 by American Heart Association, Inc.